WEKO3
-
RootNode
アイテム
Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
http://hdl.handle.net/10422/00012981
http://hdl.handle.net/10422/000129816e9f1d7e-34af-470f-8ad8-db826a54fba3
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-05-26 | |||||
| タイトル | ||||||
| タイトル | Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Hepatocellular carcinoma | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Lenvatinib | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Personalized pharmacotherapy | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Pharmacokinetics | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
NODA, Satoshi
× NODA, Satoshi× IIDA, Hiroya× FUJIMOTO, Takehide× WAKASUGI, Yoshinori× YABUTA, Naoki× SUDOU, Masatomo× HIRA, Daiki× TANI, Masaji× ANDOH, Akira× Morita, Shin-Ya× TERADA, Tomohiro |
|||||
| 著者別名 |
野田, 哲史
× 野田, 哲史× 飯田, 洋也× 藤本, 剛英× 若杉, 吉宣× 薮田, 直希× 須藤, 正朝× 平, 大樹× 谷, 眞至× 安藤, 朗× 寺田, 智祐 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: We aimed to evaluate exposure-toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC). |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Methods: In this retrospective, observational study, 28 HCC patients who had been treated with lenvatinib were enrolled between August 2018 and April 2020. We evaluated the association between the trough lenvatinib concentration and occurrence of grade ≥ 3 toxicities. Additionally, we estimated the association of the trough lenvatinib concentration with responder status (disease control; complete response, partial response, or stable disease), and progression-free survival (PFS). |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Results: The mean trough lenvatinib concentration was significantly higher in the group with grade ≥ 3 toxicity (n = 15) than in the group with grade ≤ 2 toxicity (n = 13). Based on the receiver operating characteristic curve, the threshold values of the trough lenvatinib concentrations for predicting grade ≥ 3 toxicities and responder status were 71.4 ng/mL [area under the curve (AUC) 0.86, 95% confidence interval (CI) 0.71-1.00; p < 0.05] and 36.8 ng/mL (AUC 0.95, 95% CI 0.85-1.00; p < 0.05), respectively. Lenvatinib concentrations of 36.8-71.4 ng/mL resulted in longer PFS than concentrations < 36.8 ng/mL and ≥ 71.4 ng /mL [median 13.3 months (36.8-71.4 ng/mL) vs. 3.5 months (< 36.8 ng/mL) and 7.8 months (≥ 71.4 ng /mL), respectively]. |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Conclusions: Considering these results, we propose that the target trough concentration of lenvatinib could be 36.8-71.4 ng/mL for maintaining disease control status and reducing grade ≥ 3 toxicity in the treatment of HCC. |
|||||
| 書誌情報 |
en : Cancer chemotherapy and pharmacology 発行日 2021-04-29 |
|||||
| 出版者 | ||||||
| 出版者 | Springer Nature | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1432-0843 | |||||
| PMID | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 33928425 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.1007/s00280-021-04286-2 | |||||
| 関連名称 | 10.1007/s00280-021-04286-2 | |||||
| 権利 | ||||||
| 権利情報 | © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Journal Article | |||||
